REG - Hikma Pharmaceutical - Director/PDMR Shareholding
31/05/2022 10:15
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220531:nRSe3882Na&default-theme=true
RNS Number : 3882N Hikma Pharmaceuticals Plc 31 May 2022
Hikma Pharmaceuticals PLC
Notification and public disclosure of transactions by persons discharging
managerial responsibilities
Said Darwazah
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Said Darwazah
2 Reason for the notification
a) Position/status Executive Chairman and CEO
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each
code
ID Code: GB00B0LCW083
b) Nature of the transaction Grant of a pledge by Darhold Limited over 1,105,000 Ordinary Shares of 10
pence each in Hikma Pharmaceuticals PLC in favour of J.P. Morgan (Suisse) SA.
Darhold Limited is defined as a Person Closely Associated with the Executive
Chairman and CEO, who is a director and shareholder of Darhold.
c) Price(s) and volume(s) Price(s): £0.00p
Volume(s): 1,105,000
d) Aggregated information Aggregated volume: 1,105,000
Price: £0.00p
e) Date of the transaction 29 May 2022
f) Place of the transaction Amman
Mazen Darwazah
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Mazen Darwazah
2 Reason for the notification
a) Position/status Executive Vice Chairman
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each
code
ID Code: GB00B0LCW083
b) Nature of the transaction Grant of a pledge by Darhold Limited over 1,105,000 Ordinary Shares of 10
pence each in Hikma Pharmaceuticals PLC in favour of J.P. Morgan (Suisse) SA.
Darhold Limited is defined as a Person Closely Associated with the Executive
Vice Chairman, who is a director and shareholder of Darhold.
c) Price(s) and volume(s) Price(s): £0.00p
Volume(s): 1,105,000
d) Aggregated information Aggregated volume: 1,105,000
Price: £0.00p
e) Date of the transaction 29 May 2022
f) Place of the transaction Amman
Mohammed 'Ali' Al-Husry
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Mohammed 'Ali' Al-Husry
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each
code
ID Code: GB00B0LCW083
b) Nature of the transaction Grant of a pledge by Darhold Limited over 1,105,000 Ordinary Shares of 10
pence each in Hikma Pharmaceuticals PLC in favour of J.P. Morgan (Suisse) SA.
Darhold Limited is defined as a Person Closely Associated with the
Non-Executive Director, who is a director and shareholder of Darhold.
c) Price(s) and volume(s) Price(s): £0.00p
Volume(s): 1,105,000
d) Aggregated information Aggregated volume: 1,105,000
Price: £0.00p
e) Date of the transaction 29 May 2022
f) Place of the transaction Amman
Peter Speirs
Company Secretary, responsible for releasing this announcement
31 May 2022
+44 (0) 20 7399 2760
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHGIGDUCUXDGDBRecent news on Hikma Pharmaceuticals
See all newsREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Hikma appoints new President of Generics business
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Block listing Interim Review
AnnouncementREG - Hikma Pharmaceutical - Annual Financial Report and Notice of AGM
Announcement